natgillin/translations-raw huggingface dataset:
In patients treated with docetaxel in combination with doxorubicin and cyclophosphamide (TAC), febrile neutropena and/or neutropenic infection occurred at lower rates when patients received primary G-CSF prophylaxis.
Med bolnicami, ki so docetaksel prejemale v kombinaciji z doksorubicinom in ciklofosfamidom (TAC), sta se febrilna nevtropenija in/ali nevtropenična okužba redkeje pojavili pri bolnicah, ki so prejemale primarno profilakso z G-CSF.
In patients treated with either 15 mg twice daily Xarelto followed by 20 mg once daily for treatment of DVT or PE, or with 20 mg once daily for prevention of recurrent DVT and PE, bleeding events occurred in approximately 27.8 % of patients and anaemia occurred in approximately 2.2 % of patients.
Pri bolnikih, zdravljenih bodisi z odmerkom 15 mg zdravila Xarelto dvakrat na dan in nato z odmerkom 20 mg enkrat na dan zaradi GVT ali PE, ali pri bolnikih, ki so prejemali odmerek 20 mg enkrat na dan za preprečevanje ponovne GVT in PE, se je krvavitev pojavila pri približno 27,8 % in anemija pri približno 2,2 % bolnikov.
In patients treated with G+ B, 79.4% received all six treatment cycles compared to 66.7% of patients in the B arm.
Med bolniki, zdravljenimi z G + B, jih je 79,4 % prejelo vseh šest ciklusov zdravljenja; v skupini, ki je prejemala B, je bilo takšnih 66,7 %.
In patients treated with Gazyvaro 8 out of 140 patients in the randomised phase and 2 out of 6 in the run in phase tested positive for ATA at 12 months of follow up.
Med bolniki, zdravljenimi z zdravilom Gazyvaro, je bilo po 12 mesecih spremljanja na protiterapevtska protitelesa pozitivnih 8 od 140 bolnikov v randomizirani fazi in 2 od 6 v uvajalni fazi.
In patients treated with Inflectra, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients.
Če se pri bolnikih, zdravljenih z zdravilom Inflectra, razvije resna sistemska bolezen, je treba posumiti na invazivno glivično okužbo, kot so aspergiloza, kandidiaza, pnevmocistoza, histoplazmoza, kokcidioidomikoza ali blastomikoza, poleg tega pa je pri teh bolnikih že zgodaj v poteku preiskav potreben posvet z zdravnikom, ki ima strokovno znanje iz diagnostike in zdravljenja invazivnih glivičnih okužb.
In patients treated with leflunomide, the parent compound, very rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported.
Pri bolnikih zdravljenih z leflunomidom, starševsko spojino, so tudiporočali o zelo redkih primerih neželene reakcije z eozinofilijo in sistemskimi simptomi (sindrom DRESS - Drug Reaction with Eosinophilia and Systemic Symptoms).
In patients treated with metoprolol clinical monitoring should be considered.
Pri bolnikih, ki se zdravijo z metoprololom, je treba razmisliti o kliničnem spermljanju.
In patients treated with nivolumab in combination with ipilimumab, the incidence of diarrhoea or colitis was 45.5% (204/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost driske ali kolitisa znašala 45,5 % (204/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of liver function test abnormalities was 27.9% (125/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost nenormalnih izvidov delovanja jeter znašala 27,9 % (125/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of nephritis and renal dysfunction was 4.2% (19/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost nefritisa ali okvare delovanja ledvic znašala 4,2 % (19/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of pneumonitis including interstitial lung disease, was 7.4% (33/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost pnevmonitisa, vključno z boleznijo pljučnega intersticija, znašala 7,4 % (33/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of rash was 63.4% (284/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost izpuščaja znašala 63 4 % (284/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of thyroid disorders was 23.7% (106/448).
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je pojavnost bolezni ščitnice znašala 23,7% (106/448).
In patients treated with nivolumab in combination with ipilimumab, the proportion of patients who experienced a worsening from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 2.8% for anaemia (all Grade 3), 1.2% for thrombocytopaenia, 0.5% for leucopoenia, 6.4% for lymphopaenia, 0.7% for neutropaenia, 4.1% for increased alkaline phosphatase, 11.9% for increased AST, 14.6% for increased ALT, 0.9% for increased total bilirubin, 2.4% for increased creatinine, 8.5% for increased amylase, 18.2% for increased lipase, 1.3% for hypocalcaemia, 0.3% each for hypercalcaemia, hyperkalemia, hypermagnesaemia, and hypernatraemia, 4.5% for hypokalaemia, and 9.2% for hyponatraemia.
Pri bolnikih, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, je bil delež bolnikov s premikom od izhodiščnih vrednosti do laboratorijskih nepravilnosti stopnje 3 ali 4 naslednji: 2,8 % za anemijo (vsi primeri stopnje 3), 1,2 % za trombocitopenijo, 0,5 % za levkopenijo, 6,4 % za limfopenijo, 0,7 % za nevtropenijo, 4,1 % za zvišanje vrednosti alkalne fosfataze, 11,9 % za zvišanje vrednosti AST, 14,6 % za zvišanje vrednosti ALT, 0,9 % za zvišanje vrednosti skupnega bilirubina, 2,4 % za zvišanje vrednosti kreatinina, 8,5 % za zvišanje vrednosti amilaze, 18,2 % za zvišanje vrednosti lipaze, 1,3 % za hipokalciemijo, 0,3 % za hiperkalciemijo, hiperkaliemijo, hipermagneziemijo in hipernatriemijo, 4,5 % za hipokaliemijo in 9,2 % za hiponatriemijo.
In patients treated with nivolumab monotherapy, the incidence of diarrhoea or colitis was 13.6% (235/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost driske ali kolitisa znašala 13,6 % (235/1.728).
In patients treated with nivolumab monotherapy, the incidence of hypersensitivity/infusion reactions was 4.1% (71/1728), including 3 Grade 3 and 2 Grade 4 cases.
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost preobčutljivostnih/infuzijskih reakcij znašala 4,1 % (71/1.728), vključno s 3 primeri stopnje 3 in z 2 primeroma stopnje 4.
In patients treated with nivolumab monotherapy, the incidence of liver function test abnormalities was 7.0% (121/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost nenormalnih izvidov delovanja jeter znašala 7,0 % (121/1.728).
In patients treated with nivolumab monotherapy, the incidence of nephritis or renal dysfunction was 3.2% (55/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost nefritisa ali okvare delovanja ledvic znašala 3,2 % (55/1.728).
In patients treated with nivolumab monotherapy, the incidence of pneumonitis, including interstitial lung disease, was 3.2% (56/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost pnevmonitisa, vključno z boleznijo pljučnega intersticija, znašala 3,2 % (56/1.728).
In patients treated with nivolumab monotherapy, the incidence of rash was 28.0% (484/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost izpuščaja znašala 28,0 % (484/1.728).
In patients treated with nivolumab monotherapy, the incidence of thyroid disorders, including hypothyroidism or hyperthyroidism, was 8.6% (149/1728).
Pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji, je pojavnost bolezni ščitnice, vključno s hipotiroidizmom ali hipertiroidizmom, znašala 8,6 % (149/1.728).
In patients treated with once daily GIOTRIF 40 mg, dose reductions due to ADRs occurred in 57% of the patients in the LUX-Lung 3 trial and in 25% of the patients in the LUX-Lung 8 trial.
Pri bolnikih, ki so enkrat na dan jemali po 40 mg zdravila GIOTRIF, so odmerek zaradi neželenih reakcij na zdravilo zmanjšali pri 57% bolnikov v raziskavi LUX-Lung 3 in 25 % v raziskavi
In patients treated with Pom + LD-Dex, no peripheral neuropathy reactions were reported to have been serious in clinical trials and peripheral neuropathy led to dose discontinuation in 0.3% of patients (see section 4.4).
Pri bolnikih, ki so bili zdravljeni s Pom + NO-deks, v kliničnih preskušanjih niso poročali o resnih reakcijah periferne nevropatije; periferna nevropatija je povzročila ukinitev odmerjanja pri 0,3 % bolnikov (glejte poglavje 4.4).
In patients treated with prolonged-release exenatide, generally 20 % reported at least one episode of nausea compared to 34 % of immediate-release exenatide patients.
Pri bolnikih, zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, so na splošno v 20 % poročali o najmanj eni epizodi navzee v primerjavi s 34 % pri zdravljenju z eksenatidom v obliki s takojšnim sproščanjem.
In patients treated with Remsima, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients.
Če se pri bolnikih, zdravljenih z zdravilom Remsima, razvije resna sistemska bolezen, je treba posumiti na invazivno glivično okužbo, kot so aspergiloza, kandidiaza, pnevmocistoza, histoplazmoza, kokcidioidomikoza ali blastomikoza, poleg tega pa je pri teh bolnikih že zgodaj v poteku preiskav potreben posvet z zdravnikom, ki ima strokovno znanje iz diagnostike in zdravljenja invazivnih glivičnih okužb.
In patients treated with TAGRISSO 80 mg once daily, dose reductions due to ADRs occurred in 2.2% of the patients.
Med bolniki, ki so prejemali zdravilo TAGRISSO 80 mg enkrat na dan, so zaradi neželenih učinkov odmerek zmanjšali 2,2 % bolnikom.
In patients treated with TMZ, whether used in combination with RT or as monotherapy following RT for newly-diagnosed glioblastoma multiforme, or as monotherapy in patients with recurrent or progressive glioma, the reported very common adverse reactions were similar: nausea, vomiting, constipation, anorexia, headache and fatigue.
Pri bolnikih, ki so se zdravili s TMZ, ne glede na to, ali je bilo zdravljenje kombinirano z obsevanjem ali samostojno po obsevanju na novo diagnosticiranega multiformnega glioblastoma ali pa samostojno zdravljenje bolnikov s ponavljajočim se ali napredujočim gliomom, so bili neželeni učinki, o katerih so najpogosteje poročali, podobni – navzeja, bruhanje, zaprtost, anoreksija, glavobol in utrujenost.
In patients treated with tocilizumab 8 mg/kg, significant improvements were noted on all individual components of the ACR response including: tender and swollen joint counts; patients and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.
V vseh študijah so med zdravljenjem z 8 mg/kg tocilizumaba v primerjavi z uporabo placeba v kombinaciji z metotreksatom ali drugimi imunomodulirajočimi antirevmatičnimi zdravili zabeležili značilno izboljšanje vseh posameznih elementov odziva ACR, vključno s številom bolečih in oteklih sklepov, bolnikovo in zdravnikovo oceno bolezni, kazalci preostalih sposobnosti, oceno bolečine in CRP.
In patients treated with Zontivity the concomitant use of heparin (including LMWH) might be associated with an increased risk of bleeding and caution is advised. (See section 4.4.)
Pri bolnikih, ki se zdravijo z zdravilom Zontivity, je lahko sočasna uporaba heparina (vključno z nizko molekularnim heparinom) povezana s povečanim tveganjem za krvavitve, zato svetujemo previdnost. (Glejte poglavje 4.4.)
In patients undergoing a hip replacement, 1.4% of the patients who completed treatment with Eliquis (27 out of 1,949) had a clotting event or died from any cause, compared with 3.9% (74 out of 1,917) of the patients taking enoxaparin.
Izmed bolnikov, ki so jim operativno vstavili umetni kolk, se je pri 1,4 % vseh, ki so zdravljenje zaključili z zdravilom Eliquis (27 od 1 949), pojavil krvni strdek ali so umrli zaradi katerega koli vzroka v primerjavi s 3,9 % (74 od 1 917) bolnikov, ki so prejemali enoksaparin.
In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin.
Pri bolnikih, ki so jim operativno vstavili umetno koleno, so številke znašale 15 % (147 od 976) za zdravilo Eliquis v primerjavi s 24 % (243 od 997) za enoksaparin.
In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands and soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
Pri bolnikih, pri katerih poteka presaditev matičnih celic ali kostnega mozga, se lahko pojavi bolezen presadka proti gostitelju (GvHD - Graft versus host disease); to je reakcija celic darovalca proti bolniku, ki prejme presadek; znaki in simptomi vključujejo izpuščaj na dlaneh in podplatih ter razjede in vnetja v ustih, na črevesju, jetrih, koži ali očeh, pljučih, nožnici in sklepih.
In patients undergoing a stem cell or bone marrow transplant, Graft versus Host Disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
Pri bolnikih, pri katerih poteka presaditev matičnih celic ali kostnega mozga, se lahko pojavi reakcija presadka proti gostitelju (GvHD - Graft versus Host Disease) – to je reakcija celic darovalca proti bolniku, ki presadek prejme; znaki in simptomi vključujejo izpuščaj na dlaneh ali podplatih ter razjede in rane v ustih, črevesju, na jetrih, koži ali na očeh, pljučih, v nožnici in na sklepih.
In patients undergoing coronary catheterisation, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of CBF before and up to 30 minutes after administration of Rapiscan (400 micrograms, intravenously).
Pri bolnikih, pri katerih se opravi koronarna kateterizacija, so uporabili Dopplerjev pulzni ultrazvok za merjenje povprečne hitrosti vrha koronarnega krvnega pretoka pred dajanjem zdravila Rapiscan in še do 30 minut po tem (400 mikrogramov, intravensko).
In patients undergoing general surgery, the initial dose should be given 2 hours pre-operatively.
Pri bolnikih, pri katerih bo opravljen splošen kirurški poseg, je treba začetni odmerek uporabiti 2 uri pred posegom.
In patients undergoing heart surgery, an increase in pulmonary artery pressure due to pulmonary vaso- constriction is frequently seen.
Pri bolnikih, pri katerih opravljajo srčni kirurški poseg, so pogosto opazili povišanje tlaka v pljučni arteriji zaradi pljučne vazokonstrikcije.
In patients undergoing hip replacement surgery
Bolniki po kirurški zamenjavi kolka
In patients undergoing knee replacement surgery
Bolniki po kirurški zamenjavi kolena
In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and
Pri bolnikih z večjimi ortopedskimi operacijami epiduralnih ali spinalnih hematomov, ki lahko povzročijo dolgotrajno ali trajno paralizo, pri sočasni uporabi fondaparinuksa in spinalne/epiduralne anestezije ali spinalne punkcije ne moremo izključiti.
In patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
Bolniki, pri katerih se izvaja mielosupresivno ali mieloablacijsko zdravljenje, ki mu sledi avtologna presaditev PBPC
In patients undergoing ovulation induction, the incidence of multiple pregnancy is increased compared with natural conception.
Pri bolnicah v postopku indukcije ovulacije je pogostnost večplodne nosečnosti v primerjavi z naravno zanositvijo povečana.
In patients undergoing peritoneal dialysis additional monitoring of fat- soluble vitamins and folic acid is recommended, since vitamin A, D, E and K levels were not measured in a clinical study in these patients.
Pri bolnikih, ki so na peritonealni dializi, se priporoča tudi nadziranje v maščobi topljivih vitaminov in folne kisline, ker ravni vitaminov A, D, E in K v klinični študiji pri teh bolnikih niso merili.
In patients using tacrolimus ointment, cases of malignancies, including cutaneous (i.e. cutaneous T Cell lymphomas) and other types of lymphoma, and skin cancers have been reported (see section 4.8).
Pri bolnikih, ki so uporabljali mazilo s takrolimusom, so opisani primeri malignomov, vključno s kožnimi (kožni T- celični limfomi), in druge vrste limfomov ter kožni rak (glejte poglavje 4.8).
In patients weighing 80 kg or more, 100 mg (the contents of
Pri bolnikih, ki tehtajo 80 kg ali več, 100 mg (vsebina
In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
Pri bolnikih, ki tehtajo 80 kg ali več, 100 mg (vsebina
In patients weighing 80 kg or more, 100 mg (the contents of 2 pre-filled syringes) 4 weeks after your last treatment, then every 4 weeks thereafter.
Pri bolnikih, ki tehtajo 80 kg ali več, 100 mg (vsebina
In patients weighing less than 80 kg, 50 mg (the contents of
Pri bolnikih, ki tehtajo manj kot 80 kg, 50 mg (vsebina
In patients weighing less than 80 kg, 50 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
Pri bolnikih, ki tehtajo manj kot 80 kg, 50 mg (vsebina
In patients where medical castration has not worked and who have no or only mild symptoms, Zytiga is of benefit when chemotherapy is not yet required.
Pri bolnikih, pri katerih kemična kastracija ni bila uspešna in nimajo simptomov oziroma imajo zgolj blage simptome, je zdravilo Zytiga koristno, kadar kemoterapija še ni potrebna.
In patients who anticipate a frequent use of CIALIS (i.e., at least twice weekly) a once daily regimen with the lowest doses of CIALIS might be considered suitable, based on patient choice and the physician’s judgement.
Pri bolnikih, ki pričakujejo pogosto uporabo zdravila CIALIS (npr. vsaj dvakrat tedensko) je morda primerno odmerjanje najnižjih odmerkov zdravila CIALIS enkrat na dan, glede na izbiro bolnika in presojo zdravnika.
In patients who anticipate a frequent use of CIALIS (i.e., at least twice weekly) a once daily regimen with the lowest doses of CIALIS might be considered suitable, based on patient choice and the physician’s judgement.
Pri bolnikih, ki pričakujejo pogosto uporabo zdravilo CIALIS (npr. vsaj dvakrat tedensko) je morda primerno odmerjanje najnižjih odmerkov zdravila CIALIS enkrat na dan, glede na izbiro bolnika in presojo zdravnika.
In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician’s judgement.
Pri bolnikih, ki pričakujejo pogosto uporabo tadalafila (npr. vsaj dvakrat tedensko) je morda primerno odmerjanje najnižjih odmerkov tadalafila enkrat na dan, glede na izbiro bolnika in presojo zdravnika.
In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician’s judgement.
Pri bolnikih, ki pričakujejo pogosto uporabo zdravila Tadalafil Mylan (npr. vsaj dvakrat tedensko) je morda primerno odmerjanje najnižjih odmerkov zdravila Tadalafil Mylan enkrat na dan, glede na izbiro bolnika in presojo zdravnika.
In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician’s judgement.
Pri bolnikih, ki pričakujejo pogosto uporabo zdravilo Tadalafil Mylan (npr. vsaj dvakrat tedensko) je morda primerno odmerjanje najnižjih odmerkov zdravila Tadalafil Mylan enkrat na dan, glede na izbiro bolnika in presojo zdravnika.
in patients who are already taking a combination of linagliptin and metformin as separate tablets; in combination with a sulphonylurea or insulin (other types of diabetes medicines) in patients who are not satisfactorily controlled on this medicine and metformin.
pri bolnikih, ki že jemljejo kombinacijo linagliptina in metformina v ločenih tabletah; v kombinaciji s sulfonilsečnino ali insulinom (drugo vrsto zdravila za zdravljenje sladkorne bolezni) pri bolnikih, pri katerih ob uporabi tega zdravila in metformina ravni niso ustrezno uravnane.
in patients who are already taking a combination of sitagliptin and metformin as separate tablets; in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of antidiabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.
pri bolnikih, ki že jemljejo kombinacijo sitagliptina in metformina v obliki ločenih tablet; v kombinaciji s sulfonilsečnino, agonistom PPAR gama, kot je tiazolidinedion, ali insulinom (tj. drugimi vrstami zdravil proti sladkorni bolezni) pri bolnikih, pri katerih bolezen ni zadostno nadzorovana s kombinacijo enega od teh zdravil in metformina.
in patients who are already taking a combination of sitagliptin and metformin as separate tablets; in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of diabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.
pri bolnikih, ki že jemljejo kombinacijo sitagliptina in metformina v obliki ločenih tablet; v kombinaciji s sulfonilsečnino, agonistom PPAR gama, kot je tiazolidinedion, ali insulinom (tj. drugimi vrstami zdravil za sladkorno bolezen) pri bolnikih, pri katerih bolezen ni zadostno nadzorovana s kombinacijo enega od teh zdravil in metformina.
in patients who are already taking the combination of vildagliptin and metformin as separate tablets;
pri bolnikih, ki že jemljejo kombinacijo vildagliptina in metformina v ločenih tabletah;
In patients who are diagnosed with RVO, treatment with trametinib, whether given as monotherapy or in combination with dabrafenib, should be permanently discontinued.
Pri bolnikih, pri katerih je med zdravljenjem s trametinibom, bodisi v monoterapiji ali v kombinaciji z dabrafenibom, diagnosticirana zapora mrežnične vene (RVO – Retinal vein occlusion), je treba zdravljenje s trametinibom trajno končati.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors or Angiotensin-II antagonists, may result in further deterioration of renal function, including possible acute renal failure.
Pri starejših bolnikih s hipovolemijo (vključno s tistimi, ki se zdravijo z diuretiki), ali z zmanjšanim delovanjem ledvic, sočasna uporaba nesteroidnih protivnetnih zdravil, vključno s selektivnimi zaviralci COX-2, zaviralci ACE ali antagonisti angiotenzina II, lahko povzroči nadaljnje poslabšanje ledvične funkcije, vključno z akutno odpovedjo ledvic.
in patients who are not satisfactorily controlled on metformin (a diabetes medicine) used on its own;
pri bolnikih, pri katerih sladkorna bolezen ni zadostno nadzorovana samo z metforminom (zdravilom za sladkorno bolezen);
in patients who are not satisfactorily controlled on metformin (a diabetes medicine) used on its own;
pri bolnikih, pri katerih sladkorna bolezen ni zadostno uravnana samo z metforminom (zdravilom za zdravljenje sladkorne bolezni);